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Abstract
Background—Within the alcoholism field, there is mounting evidence supporting an important
relationship between medication adherence and drinking outcomes. Little is known however,
about the complex relationships between medication and treatment variables and drinking
outcomes. The present paper reports on the differential impact of medication adherence and
treatment factors on drinking outcomes. Data derived from the COMBINE Study was used to
investigate the interrelationships between medication adherence, combination treatments and
drinking outcomes.
Methods—Twelve hundred and twenty-six patients were randomized to one of eight different
combination treatments involving two medications - naltrexone and acamprosate and placebo, and
two behavioral treatments - medical management (MM) and combined behavioral intervention
(CBI). Two primary drinking outcomes were percent days abstinent (PDA) and time to first heavy
drinking day. Medication adherence was defined as a proportion that reflects the number of pills
taken by the maximum number of pills expected to be taken over the course of the trial. A
generalized linear mixed model was used to estimate the effects of adherence on PDA while
proportional hazards model was used to examine similar co-variate effects on time to first heavy
drinking day.
Corresponding author: Allen Zweben, DSW, School of Social Work, Columbia University, 1255 Amsterdam Avenue, New York,
N.Y. 10027, Phone number: 212 851 2387, Fax number: 212 851 2205, E-mail: az173@columbia.edu.
Data presented in this report were collected as part of the multisite COMBINE trial sponsored by the National Institute on Alcohol
Abuse and Alcoholism, in collaboration with the COMBINE Study Research Group. The Combine study was supported by National
Institute on Alcohol Abuse and Alcoholism (NIAAA) Cooperative Agreements U10AA11715, 11716, 11721, 11727, 11756, 11768,
11773, 11776, 11777, 11783, 11787, 11799, and 11773 and by career scientist awards K05AA014715, K05AA00133, K24DA022288
and K23AA00329. A full listing of the staff of the COMBINE Study can be found at http://www.cscc.unc.edu/combine/.
NIH Public Access
Author Manuscript
Alcohol Clin Exp Res. Author manuscript; available in PMC 2009 September 1.
Published in final edited form as:













Results—Concerning time to first heavy drinking day, a significant three-way interaction was
found between medication adherence, CBI and naltrexone (p=0.0160). Within the MM only plus
placebo group (no CBI), significant differences were found in “recovery” (i.e., no heavy drinking
days) rates between adherers and noadherers (40% vs. 10%, p<0.0001). Such differences became
nonsignificant (p = .12) when CBI was introduced into the relationship. CBI did not add any such
advantage to naltrexone-treated patients.
Conclusions—CBI might serve a protective function for nonadherers in the placebo group; the
median relapse time was reduced when these nonadherers were exposed to the alcohol specialty
intervention. CBI offered little additional benefit to nonadherers in the naltrexone group. Among
nonadherers in the naltrexone group, relapse rates appear to be more a function of inadequate
exposure to the active medication and less influenced by CBI.
Keywords
Naltrexone; Acamprosate; Medication Adherence; Combined Behavioral Intervention (CBI);
Medical Management (MM)
INTRODUCTION
Within the alcoholism field, there is mounting evidence supporting an important relationship
between medication adherence and treatment outcomes (Chick, et al., 2000; Pettinati, 2006;
Volpicelli et al., 1997; Weiss, 2004; Zweben and Zuckoff, 2002). Pharmacotherapy that is
proven for its therapeutics in reducing acute withdrawal symptoms and/or urges to drink
alcohol or use of other drugs is effective when patients adhere to the prescribed medical
regimen. In addition, behavioral treatment employed in combination with medication can
facilitate medication adherence. Behavioral therapy can be used to address patient concerns
related to adverse reactions to the medication while improving coping skills, building
supportive relationships for taking medication for chronic conditions, and strengthening
motivation to change (Carroll, 1997). These factors are not only relevant to improving
medication adherence but to sustaining the benefits of change as well.
More is known about the impact of medication adherence on treatment outcome in
naltrexone studies than in acamprosate trials (Pettinati, 2006). Specifically, several placebo-
controlled naltrexone studies have demonstrated a significant relationship between good
adherence to medication and behavioral treatment regimens and successful treatment
outcomes (Baros et al., 2007; Cramer et al., 2003; Onken et al., Volpicelli et al., 1997; Oslin
et al., in press). For example, Volpicelli et al., (1997) tested the efficacy of naltrexone in an
alcohol dependent population and discovered significant differences in outcomes between
those who took their medication regularly and those who did not; medication-adherent
patients had a 14% relapse rate in contrast to 50% in the nonadherent group. These authors
also found significant differences between naltrexone and placebo patients in drinking
outcomes only among patients that took their medication regularly. Placebo-adherent
patients had a relapse rate of 50% in comparison to 25% of the naltrexone-adherent group.
In contrast, among individuals with low medication adherence, no significant differences
were observed between naltrexone and placebo patients on drinking measures. These
differences in outcomes between placebo and naltrexone-treated patients appeared to be
moderated by medication adherence.
Similar findings have been reported by Cramer and her colleagues (2003). These researchers
found that pill adherence was a better predictor of drinking outcomes than naltrexone
treatment in the first 13 weeks of treatment. Similar findings have been reported by Fuller et
al., (1986) in their study testing the effects of disulfiram on alcohol dependent patients.
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Fuller et al., (1986) found no significant differences in abstinence rates between placebo and
active medication conditions but did find a significant relationship between pill adherence
(i.e., active and inactive medications) and drinking outcomes in the total sample. Together
these findings on medication adherence rates might explain why discrepancies in outcomes
have been reported across naltrexone trials (Kranzler et al., 2000).
Other studies have reported a significant interaction between medication adherence,
behavioral therapy and treatment outcomes. Baros et al., (2007) tested the combined efficacy
of behavioral treatment and naltrexone and found a doubling in the effect size of the
medication by therapy interactions when the analysis was performed only on the subgroup
of naltrexone-adherent patients. Among those receiving naltrexone and cognitive behavioral
therapy (CBT), the likelihood of decreasing drinking was greater if patients took their study
medication as prescribed. Improved outcomes were typically observed in the sample
population with 80% adherence to the prescribed medication.
It should be noted that there may are a number of individual and contextual factors that may
further moderate the relationship between medication adherence and treatment outcome in a
trial involving behavioral and/or pharmacological therapies (see e.g., Moos et al., 2002;
Moos & Moos, 2003; Joe, et al., 1991). ). In medical programs, low medication adherence
rates has been shown to be more damaging for patients with chronic disorders such as
hypertension and diabetes than those with acute disorders (Weiss, 2004). In substance use
programs, adherence to methadone (as defined by dosage level) may be further moderated
by patient satisfaction, prior treatment history, patient motivation, early program
involvement and the kinds and amounts of services received in the first 3 months of
treatment (Joe, et al, 1991; Simpson, et al., 1997; Zang et al., 2003). Further, in substance
use programs which involve behavioral treatments, the relationship between treatment
adherence and outcome may be moderated by such matters as outcome expectancies of
patients, inadequate planning and a poor working alliance between therapist and patient
(Moos, 2005) In other words, medication adherence, albeit important, may interact with a
variety of circumstances and conditions to produce different outcomes.
To have a better understanding of the nature of relationship between medication adherence
and outcomes, more rigor is required to investigate the topic. Most studies of adherence lack
sufficient power to test the complex relationships between medication adherence, treatment
variables and drinking outcomes. Outcome studies typically report medication adherence
rates, but rarely do they report comparisons between patients with good vs. poor medication
adherence across different kinds of treatment modalities. Thus, much more needs to be
known about the differential impact of medication adherence on alcohol patients involved
with different medications and behavioral treatments. The present paper reports on the
findings on the relationship between medication adherence and drinking behavior in a large
scale, multi-site, combined medication and behavioral treatment, namely, the National
Institute on Alcohol Abuse and Alcoholism’s COMBINE Study.
METHODS
The COMBINE Study Design
The COMBINE Study tested combinations of two medications, naltrexone and acamprosate
and two behavioral treatments, low-intensity medical management (MM) and moderately
intensive combined behavioral intervention (CBI). A total of 1383 patients were randomized
to one of nine treatment conditions after 4 days of abstinence and followed up at 68 weeks
post randomization. Eight of the cells involved a medication/placebo and behavioral
treatment combinations. A ninth cell involved CBI only (no pills).
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The overall aim of the current study was to test whether differences in medication adherence
rates across the 8 treatment combinations would yield different drinking outcomes. It was
hypothesized that higher medication adherence rates across the various treatment
combinations would produce better drinking outcomes in the study group. In line with the
aforementioned objective, only patients who received medication or placebo equivalents
were included in the analysis. The CBI only, no-pill condition (cell 9) was excluded in the
analysis of the findings on analysis of medications adherence.
The study sample was comprised of 1226 patients in the 8 medication/placebo (i.e., 8 cells)
conditions. All patients that received study medication or placebo were also assigned to
MM. Approximately 38% (465) of the 1226 patients that received study medication/placebo
also received CBI (along with MM). Table 1 lists the eight medication/placebo treatment
combinations along with the CBI only condition. To be eligible, individuals had to meet
DSM-IV criteria for alcohol dependence and be seeking treatment; those individuals who
were medically unstable, had serious psychiatric problems, or were drug dependent in the
past 6 months were excluded. (For a full description of the methodology employed in the
COMBINE Study see Pettinati et al., 2005).
Behavioral Treatments
Medical Management (MM) was primarily focused on enhancing medication adherence and
providing support for achieving abstinence (Pettinati et al., 2004) ). MM was derived from
brief interventions that have been employed opportunistically as stand-alone treatments in
nonspecialty health care settings, or as behavioral platforms for pharmacotherapies. Many of
the components of brief interventions were adopted for MM in the COMBINE trial. To
enhance the ecological validity of this primary care type model, except for the initial session
which averaged 45 minutes, MM sessions were kept to an average of 20 minutes in duration.
Patients were expected to attend 9 MM sessions over 16 weeks. The content of the sessions
was focused on relaying alcohol-related information, facilitating medication adherence,
managing medication side effects, actively referring to Alcoholics Anonymous (AA), and in
general, providing support for abstinence.
Combined Behavioral Intervention (CBI) was comprised of three effective components of
behavioral interventions – i.e., motivational enhancement therapy (MET) cognitive-
behavioral therapy (CBT) and twelve-step facilitation (TSF) (Miller, 2004). CBI involved
some degree of flexibility in session attendance dependent upon treatment goals and
progress. Patients could attend as many as 20 sessions over 16 weeks with each session
averaging 50 minutes. To enhance the applicability of the combined behavioral intervention
(CBI), a variety of “pull-out” procedures were developed. These procedures addressed
sundry clinical issues which often arise over the course of treatment such as no-shows,
cancellations or missed appointments, medication nonadherence and everyday hardships
(housing, financial, and legal problems). Also, different modules were designed to address
patient difficulties in a number of areas such as communication problems, psychiatric
symptoms and other problems. Attendance at mutual support groups such as Alcoholics
Anonymous (AA) was supported particularly for those who lacked abstinence-related
support. Patients were asked to identify a supportive significant other (SSO) and were
encouraged to bring the SSO to the sessions. Motivational interviewing strategies and
techniques were employed in all components of CBI.
Assessment Measures
Two primary drinking outcomes were percent days abstinent (PDA) and time to first heavy
drinking day, defined as 5 or more drinks for men and 4 or more drinks for women per day.
Drinking outcomes were derived from the Form 90 (Miller et al., 1996) administered at
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baseline and the Timeline- Followback (Sobell and Sobell, 1996) administered during the
16-week treatment period. These two instruments assess daily drinking. Summary scores are
derived from the daily drinking record to provide temporal drinking practices (i.e., episodic,
binge and steady drinking).
The COMBINE research protocol was focused on achieving maximum exposure to the
medication and placebo equivalents. The extent to which patients ingested the full dose of
the medications or placebo equivalents comprised the definition of medication adherence.
Patients were expected to take 8 pills daily (100 mg. of naltrexone and/or 3,000 mg. of
acamprosate or the placebo equivalents) for 112 days or 896 pills during the treatment phase
of the study. Patients were assigned a proportion that reflected the number of pills taken by
the maximum number of pills expected to be taken over the course of the trial. Thus a
patient ingesting 800 pills over the course of the treatment would have had an exposure rate
of 800/896 or 0.89. Dose reductions were allowed if side effects persisted or were recurrent.
However, patients were returned to the expected dosage when side effects disappeared or
were reduced.
Adherence was computed from the pill count records for 1226 patients randomized to the 8
medication conditions. Individuals who were nonadherent to the medication or who
withdrew from the study had all available information used in the computation of adherence
so that proportions of the full protocol dose varied from 0.0 to 1.0. For purposes of testing
and interpreting the effects of medication adherence on treatment outcomes, we categorized
patients as adherent or nonadherent depending upon whether they had taken 80% or more of
the maximum number of pills during treatment. An 80% cut-off point for medication
adherence has been employed in clinical trials of naltrexone and other medications (Baros et
al., 2007; Chick, et al., 2000; Osterberg and Blaschke, 2005; Pettinati et al., 2000).
Exposure to the behavioral treatments was defined by the amount of session attendance. The
session check list for MM and CBI was used to measure adherence to treatment visits.
Individuals were expected to attend on average 9 MM sessions and between 12 to 16 CBI
sessions over the 16-week treatment period.
Treatment withdrawal or drop-out was measured differently for the behavioral treatments
(MM and CBI). Individuals missing 3 consecutive MM or CBI sessions or not attending any
CBI or MM sessions for a period of one month were considered drop-outs in the study.
Patients categorized as drop-outs were treated as relapsed (i.e., returning to heavy drinking)
in the data analysis. Treatment attendance was monitored by the COMBINE Coordinating
Center (CC).
Statistical Analysis
As mentioned earlier, this report is based on 1226 patients randomized to the 8 medication/
treatment combinations. A generalized linear mixed model was used to estimate the effects
of the study treatments on differences in PDA over time. A mixed linear modeling strategy
is suited to the variable number of repeated measurements obtained for each subject while
adjusting for adherence covariates and the 3-way factorial design of study treatments. The
effect of the three treatment factors (i.e., acamprosate, naltrexone and CBI) on time to first
heavy drinking day was assessed with a proportional hazards model. Adjustments were
made for baseline PDA, adherence status, and clinical site for all two- and three-way
interactions with treatment effects. The statistical methods employed were identical to those
reported earlier (Anton et al., 2006) which followed a pre-specified approach to analyzing
the primary drinking outcomes. Exploratory analysis was evaluated at the nominal p = 0.05
level of significance.
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A total of 1226 patients comprised the total study population (69% men and 31% women).
Of this sample, 42% were married and the average age of the group was 44 years. A sizeable
proportion (23%) of the patients were categorized as ethnic minorities (i.e., 8% African-
American, 11% Latino and 4% Other). The majority of individuals had at least a high school
education (69%). Baseline data on alcohol consumption revealed the following: (1) the mean
number of heavy drinking days in the 30 days prior to treatment was 19.6; (2) the mean
number of drinks per drinking day was 12.6; and (3) the percentage of days drinking was
75%. Except for one finding, there were no significant differences in the 76 pretreatment
characteristics that were compared across various treatment combinations (Anton et al.,
2006); there was small but significant difference in the number of alcohol dependence
symptoms between MM and MM+CBI conditions (5.6 vs. 5.4 symptoms, respectively, p
<0.05). Given the number of comparisons made, it is conceivable that the latter finding
might be spurious. (For a full description of the sample, see Anton et al., 2006).
Medication Adherence by Medication Condition
In general, data from this study show that the combination medication (acamprosate and
naltrexone) conditions had significantly lower adherence rates than the placebo condition
(See Table 2 below). Overall, individuals receiving acamprosate + naltrexone consumed
fewer pills than those in the placebo group (64.9% vs. 76.2%, of the expected dose of 896
pills, p<0.01). These differences were consistent across both MM only and MM + CBI
conditions. In addition, adding acamprosate to naltrexone appeared to result in lower
adherence rates than providing naltrexone alone; significant differences were found between
the combination medication condition (acamprosate and naltrexone) and the naltrexone
alone condition (64.9% vs. 72.2%, respectively (p = 0.01). Moreover, significant differences
were found between acamprosate and placebo conditions. (69.7% vs. 76.2%, respectively,
p< 0.05) but not between the naltrexone and placebo conditions (ns). Finally, it should be
important to note that individuals who failed to take their medication regularly were more
likely to stop or withdraw from the medication completely. Thus, mean adherence rates to
the expected dosage was 36.1 % for withdrawers in contrast to 90.02 % for nonwithdrawers
(p= 0.001).
Medication Adherence by Behavioral Treatment Modality
In examining the relationship of behavioral treatments to medication adherence, we initially
compared medication adherence between those receiving MM alone and those receiving the
more intensive alcohol specialty treatment (i.e., CBI + MM). Contrary to prior expectations,
we found that adding CBI to MM did not produce better results than those patients receiving
only the MM behavioral intervention; that is, both MM only and MM+CBI were equally
effective in sustaining a commitment to the medication regime. In the MM only vs. MM
+CBI conditions, mean adherence to the full medication regime was 71.8% vs. 69.8%,
respectively (ns).
We also conducted another analysis examining whether sessions attendance was related to
medication adherence. As expected, there was a highly significant association found in
medication adherence rates (≥ 80% maximum dose exposure) between individuals attending
at least 7 MM or MM+CBI sessions and those that did not. Approximately 75% of the high
treatment attendees ((7 or more sessions) in both behavioral treatments (i.e., MM only and
MM+CBI) were categorized as medication adherent (≥ 80% maximum dose exposure)
(p<0001). In contrast, 25% of low treatment attendees in both behavioral treatments were
placed in the medication adherent category (p<0001).
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In addition, rates of withdrawal from medications were not significantly different between
MM only and MM+CBI (37% vs. 34%, respectively, ns). Thus, patients were just as likely
to take their pills regardless of whether they were assigned to only a low intensity,
nonspecialty treatment (MM) or to an additional moderately intensive, alcohol specialty
treatment (MM+CBI). Of interest is whether CBI session attendance improved or reduced
MM session attendance. The findings show that there were no significant differences in MM
session attendance between MM only and MM+CBI patients. Mean number of MM sessions
attended for MM only patients was 7.44 vs. 7.65 for the MM+CBI patients (ns).
Consequently, participating in CBI did not enhance or impede MM attendance.
Medication Adherence and Primary Drinking Outcome: PDA and Time to First Heavy
Drinking Day
To examine the effects of medication adherence on PDA across all treatment combinations
we employed a generalized linear mixed model adjusting for baseline PDA and clinical site.
As indicated earlier, patients were also categorized as adherent or nonadherent depending
upon whether they had taken 80% or more of the full dose medication or placebo during
treatment. Results of these analyses can be found on Table 3.
As in other medication trials, nonadherents to the study medication did more poorly than
adherents. At the end of week 16, mean PDA for adherent patients was 82% vs. 72% for
nonadherent patients (p<0.0001). Further, in adjusting for the maximum dose adherence
(i.e., ≥ 80% of the pills) we discovered a medication by therapy interaction. As observed on
Table 3, a significant interaction was found between naltrexone and CBI with the
naltrexone/no CBI group (i.e., MM only) having the highest mean PDA (79.84%) and the
placebo/no CBI group having the lowest PDA (73.93%) at week 16 (p= 0.01). No other
interactions were significant. These data are very consistent with our primary intent- to- treat
outcome analysis where a similar interaction was found (See Anton et al., 2006).
To examine the relationship between medication adherence and time to first heavy drinking
day, we employed a proportional hazards regression model adjusting for site and baseline
PDA with placebo+MM as the reference group. For clinical interpretation, we classified
patients (i.e., the numbers and proportions) as having relapsed if they had one or more heavy
drinking days during treatment. To conduct a more parsimonious analysis, so that no
assumptions would be required for medication adherence, we only included patients who
had complete data on treatment delivery and drinking (e.g., Timeline Follow Back) at the
end of 16 weeks (n = 1147).
Results of these analyses can be found on Table 4. As with PDA, the risk was significantly
reduced if patients remained adherent (80% or more maximum dose adherence) to the active
or inactive medication (H.R. 0.439, CI 0.319–0.605, p<.0001). These data also show a
relationship between adherence and the behavioral treatment modality. As in the primary
outcome paper (Anton et al., 2006), there was a significant main effect for naltrexone for the
time to first heavy drinking day. The reduction of risk for relapse was enhanced when
patients remained adherent to the study medication. The relapse hazard ratio was 0.476 (CI
0.340–0.666, p< .0001) for patients who were adherent to naltrexone in contrast to those
who were adherent to the placebo. The table also shows a main effect that almost reaches
significance for acamprosate (p= .06). However, what we are likely seeing are the positive
effects of adherence to treatment in general, since patients that received both active
naltrexone and active acamprosate were also included in the acamprosate main effect group
due to the factorial design.
Of major interest is the three-way significant interaction between medication adherence,
naltrexone and CBI (p = 0.016). With regard to time to first heavy drinking day, medication
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adherence, CBI and naltrexone appear to have a differential impact on the study population.
The reduction of risk for relapse appears to be dependent upon whether the patients were
medication adherent, received CBI and/or naltrexone.
The figures below (1a, 1b, 2a, and 2b) illustrate how to interpret clinically the three-way
interaction between naltrexone, medication adherence and CBI. The figures give the
probabilities of not returning to heavy drinking at various time periods over the 16-week
treatment period. These probabilities are expressed as cumulative proportions (i.e.,
percentages) in these figures.
In Figure 1a, we examined differences in drinking outcomes between adherers and
nonadherers who were not assigned to an active medication (no naltrexone or double
placebo) and an intensive treatment condition (MM only). These data revealed that the
probability of not returning to heavy drinking (i.e., nonrelapse) is higher for adherers than
nonadherers in this assignment category. More specifically, 10% of the nonadherers who
were not assigned to both an active medication condition and a more intensive treatment
modality (i.e., received double placebo and MM only) had not relapsed (i.e., had no heavy
drinking days) by the end of the study. In contrast, 40% of adherers in MM only and
placebo condition were placed in this remitted or recovering category (p<0.001). In short,
the “recovery” rate among adherers in the MM only, placebo condition was quite striking
when compared to the nonadherers in the same condition. Thus in the absence of both CBI
and naltrexone (MM only with double placebo or no naltrexone), adherence seems to be one
of the factors in decreasing the overall hazard of relapse.
In Figure 1b we investigated differences in drinking outcomes between adherers and
nonadherers who were assigned to a double placebo (i.e., no active medications or no
naltrexone) condition and a more intensive treatment condition (CBI). Unlike patients in
Figure 1a, all patients in Figure 1b received CBI along with MM. These data show that the
probability of maintaining sobriety (i.e., no heavy drinking days) for nonadherent placebo
patients was higher if they received CBI than if they did not. More precisely, in the absence
of an active medication but in the presence of CBI, differences in recovery rates (i.e. no
heavy drinking days) between adherers and nonadherers is less pronounced than the
patients in Figure 1a. Among patients receiving placebo + CBI, approximately 25% of the
nonadherers (<80% of the full dose) had not resumed heavy drinking by the end of the 16
week treatment period whereas 35% of adherers (≥ 80% of the full dose) in the same
condition (i.e., double placebo and CBI) were placed in the non-relapsed category (p =.12,
ns). In other words, differences between adherers and nonadherers to the inactive
medication condition became non-significant when CBI was introduced into the relationship
thereby suggesting that exposure to CBI may decrease the risk of relapse secondary to pill
nonadherence.
Figures 2a and 2b compare the recovery patterns between nonadherent and adherent among
patients receiving an active medication (naltrexone). In Figure 2a, naltrexone-treated
patients were assigned to MM only whereas their counterparts in Figure 2b received MM
+CBI. Overall, these two figures demonstrate that the probability of recovery (i.e., returning
to heavy drinking) essentially remained the same whether or not they were assigned to the
more intensive treatment condition (i.e., CBI).
Figure 2a shows that in the absence of CBI, the amount of exposure to naltrexone seemed to
make a significant difference in decreasing the risk of relapse over the 16-week treatment
period. At the end of 16 weeks, the percentage of adherers that maintained sobriety (i.e.,
having no heavy drinking days) was almost double that of nonadherers (42% vs. 22%, p= 0.
022). Figure 2b shows that there is almost no change in drinking outcomes (i.e., relapse to
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heavy drinking) between adherers and nonadherers when exposed to CBI; differences in
relapse rates between these two groups remained virtually the same as in Figure 2a despite
the exposure to CBI (39% vs. 21%), p = 0.026). In brief, adding CBI did not have an impact
on the relapse rates relative to the no CBI group among naltrexone-treated patients,
In summary, among patients receiving placebo, the rates of change in drinking behavior
between adherers and nonadherers appear to differ in accordance with the presence and
absence of CBI. The highest rates of relapse to heavy drinking was found in the placebo
group unless they were exposed to CBI, which then lowered (mediates non-adherence to
pills) the relapse rates. Among naltrexone-treated patients, the magnitude of change between
naltrexone adherers and nonadherers remained essentially the same whether or not patients
were exposed to CBI. Such findings suggest that differences in outcomes between adherers
and nonadherers may be related to the amount of exposure to the active medication
(naltrexone) and are less influenced by CBI.
DISCUSSION
This paper examined the relationship between medication adherence and drinking outcomes
at 16 weeks, the time period between treatment entry and treatment completion. More
specifically, we addressed whether there were differences in medication adherence rates
across 8 medication/behavioral treatment combinations. We also investigated whether there
were differences in medication adherence between the two behavioral treatment modalities
(i.e., combined behavior intervention (CBI) + medical management (MM) vs. MM only).
Additionally, we examined whether differences in medication adherence rates across the 8
combinations were associated with differences in drinking outcomes. Answers to these
questions were expected to further our understanding of the interrelationship between
medication adherence and treatment outcome
Data revealed significant differences in pill taking adherence rates between the combination
medications (naltrexone + acamprosate) and the double placebo conditions. Similarly,
significant differences in pill taking adherence rates were found between acamprosate +
naltrexone placebo and the double placebo conditions but not between the naltrexone +
acamprosate placebo and the double placebo conditions. Also, significant differences in pill
taking adherence rates were revealed between the combination medications (naltrexone +
acamprosate) and the naltrexone + acamprosate placebo conditions. These findings were
consistent across behavioral treatments.
Individuals that received acamprosate only exhibited prominent side effects and lower
adherence rates than the double placebo group. Consequently, it would seem that adding
acamprosate to naltrexone lowered the adherence rates of patients assigned to this
combination medication condition. The higher number of reported side effects in the
combination conditions could account for these differences. For example, nausea was
present in 42.4% of the combination group (acamprosate and naltrexone) in contrast to
21.2% in the placebo conditions (p = 0.05) (Ciraulo, 2007). Similar findings were observed
with regard to other adverse effects such as vomiting and diarrhea (p = 0.05) (Ciraulo,
2007). These findings are comparable with other drug trials where pill adherence rates are
typically higher for patients in the placebo than in the active medication groups (Osterberg
and Blaschke, 2005).
Moreover, those patients who failed to take their medication regularly were also more likely
to stop their medication completely. This is important to note since those who stopped
taking their medication were also more likely to resume drinking than those who continued
taking the medication until the end of treatment; the average PDA for medication
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withdrawers was 65.9% in contrast to 80.7% among nonwithdrawers (p<0.0001). These
findings are in agreement with Rohsenhow and her colleagues (2000) who found that a
higher severity of side effects such as nausea and vomiting predicted nonadherence among
naltrexone-treated patients and might also contribute to poorer drinking outcomes in an
alcohol-dependent population.
Concerning the relationship between medication adherence and behavioral treatments, the
more intensive, specialty treatment CBI, did not perform better than the less intensive,
primary care type MM approach. There were no significant differences in both adherence
and medication discontinuance rates between MM alone or in combination with CBI. Such
findings are consistent with other alcohol medication trials involving naltrexone (Baros et
al., 2007; Oslin et al., in press). Baros et al., (2007) found no significant differences in
medication adherence rates between the more intensive cognitive behavioral therapy (CBT)
and the less intensive motivational enhancement therapy (MET). Similarly, Oslin et al., (in
press) in testing the effects of naltrexone among alcohol patients assigned to behavioral
interventions of varying intensities (e.g., compliance enhancement (CE), doctor only and
cognitive behavioral therapy, found no significant differences between the three contrasting
behavioral approaches in facilitating medication adherence.
As expected, high medication adherence fared better than low medication adherence with
regard to PDA and time to first heavy drinking day. With regard to PDA, we found a
significant interaction between naltrexone and CBI with the naltrexone/MM only group
having the highest PDA and the placebo/MM only having the lowest PDA. These results are
comparable to the COMBINE Study primary intent-to-treat outcome findings (Anton et al.,
2006). As in the current paper, the results of the main outcome paper show PDA highest in
the naltrexone/no CBI (i.e., MM only) group (80.6%) and the lowest for the placebo/no CBI
group (75%, p = 0.0009). In short, drinking outcomes (i.e., PDA) of the COMBINE study
did not change when pill taking adherence status was introduced into the analysis, thereby
strengthening the conclusions drawn from the main outcome paper.
With respect to first heavy drinking day, a significant three-way interaction was found
between medication adherence, CBI and naltrexone. Lower relapse rates appeared to be
dependent upon whether the patient was adherent to medication and received naltrexone or
CBI. Within the placebo group, CBI seems to have had a beneficial impact on decreasing the
odds of returning to drinking among patients nonadherent to pill taking. In the presence of
CBI, the recovery (non-relapse) period for patients who were nonadherent to placebo was
extended. CBI may have provided these nonadherent patients with an increased level of
support that resulted in a reduction in heavy drinking. Other components of CBI such as
increasing coping skills to deal with cravings or drink refusal strategies, providing optimism
for change and enhancing self-efficacy might have been useful in extending the recovery
period.
In contrast, among naltrexone-treated patients, CBI demonstrated no significant additional
benefit beyond what was produced by exposure to the active medication in the context of
medical management. Unlike the placebo group, ongoing adherence to the study medication
may have helped to reduce the likelihood of relapse with CBI providing minimal additional
benefit. The findings on the three-way interaction indicate that effects of medication on
outcomes are moderated by both medication and CBI, such that CBI provides a buffer for
nonadherence in the placebo but not in the medication condition.
In interpreting the results on the three-way interaction, consideration should be given to why
CBI did not have a noticeable impact on naltrexone-treated patients. MM was primarily
designed to maximize and support pill taking adherence. Consequently, maximum dose
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medication adherence rates were relatively high across MM treatment combinations. Thus, it
is conceivable that since MM had a strong focus on adherence, it may have caused a “ceiling
effect” on this outcome variable such that any additional work on adherence via CBI may be
less potent or observable. It is also conceivable that CBI inadvertently helped these
naltrexone-treated patients to be less concerned about not taking or stopping the medication.
CBI emphasizes decision-making responsibilities and promotes self-efficacy on the part of
patients. Such an approach may have indirectly empowered or allowed patients to stop
taking the medication if they felt it was not working (i.e., experiencing side effects).
It is not clear which components of CBI have benefited or not benefited nonadherent
patients. A process analysis aimed at examining mechanisms of action associated with CBI
and medication adherence might provide further understanding of how this treatment
modality impacts on alcohol patients (Stout, 2007).
In summary, high medication adherents fared better than low medication adherents across all
combinations. CBI seemed to have a beneficial impact on nonadherents in the placebo
condition raising the issue of whether CBI may serve as a cushion or have a protective
function for nonadherent, placebo patients. On the other hand, adherence to naltrexone
provided a significant increase in time to relapse. However, CBI did not add any such
advantage to naltrexone-treated patients.
The current study adds to the growing literature (see e.g., O’Malley et al., 2003; Garbutt et
al., 2005) supporting the use of a primary care approach as a behavioral platform for
pharmacotherapy with alcohol dependent patients. It confirms the findings of the primary
COMBINE Study report (Anton et al. 2006) which showed MM to be beneficial for a
sizeable proportion of patients regularly taking naltrexone. However, the MM approach was
utilized in a clinical trial. Consequently, other factors, unrelated to the treatment approach
(e.g., conducting an extensive assessment battery, repeated contact with research staff, and
follow-up visits) could account for the positive findings (Clifford et al., 2007). Thus, MM
will need to be adapted to “real world” medical settings like primary care clinics, to
determine the feasibility and utility of the approach.
In conclusion, there are several new treatment strategies for alcohol dependent patients,
involving pharmacotherapies, behavioral interventions, or the combination. The success of
these treatments is strongly tied to good patient medication adherence and visit attendance at
behavioral interventions. In studies like the COMBINE study, where medication adherence
rates and session attendance rates are high, treatment outcomes reported for the total study
group in an intent to treat analysis, as previously reported, were not substantially altered by a
retrospective analyses that considered medication adherence. However, in clinical practice
these issues must be considered.
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Figure 1a & 1b. Cumulative proportion of Patients with No Heavy Drinking Days during
treatment between Adherers and Nonadherers: No Naltrexone (placebo Naltrexone) by
Combined Behavioral Intervention (CBI) therapy groups
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Figure 2a and 2b. Cumulative proportion of Patients with No Heavy Drinking Days during
treatment between Adherers and Nonadherers: Naltrexone by Combined Behavioral
Intervention (CBI) therapy groups
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Table 2
Comparison of Pill Adherence Rates between Medication/Treatment Combinations (N = 1224)++
Medication group MM Only MM+CBI Total for Medication Group












65.4 (34.1)** 74.1 (30.7)** 69.7 (32.7)*
Naltrexone + Acamprosateb
(n= 305) 65.8 (35.6)
** 64.1 (34.6)*** 64.9 (35.0)***
++
Two observations were missing in these data
MM = Medical Management
CBI = Combined Behavioral Intervention
a
Significance levels reflect comparisons with naltrexone + acamprosate
b
Significance levels reflect comparisons with placebo
*
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Table 3
Tests of Percent Days Abstinent (PDA) at Baseline and Week 16 Adjusted for Full Dose Adherence:
Naltrexone X Combined Behavior Intervention (CBI) Interaction (N=1226)
Baseline Mean s.e. Week 16 Adjusted Mean s.e.
Naltrexone/CBI (n=312) 25.34 1.405 76.48 1.44
Naltrexone/No CBI (n=302) 26.59 1.433 79.84 1.46
No Naltrexone/CBI (n=307) 25.08 1.460 77.81 1.51
No Naltrexone/No CBI (n=305) 24.68 1.432 73.93 1.47
CBI = Combined Behavior Intervention
All differences are statistically significant at p = 0.01
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